- Home
- BUD vs REGN Comparison
BUD vs REGN Comparison
Compare BUD & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUD
- REGN
- Stock Information
- Founded
- BUD 1366
- REGN 1988
- Country
- BUD Belgium
- REGN United States
- Employees
- BUD N/A
- REGN N/A
- Industry
- BUD Beverages (Production/Distribution)
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- BUD Consumer Staples
- REGN Health Care
- Exchange
- BUD Nasdaq
- REGN Nasdaq
- Market Cap
- BUD 98.8B
- REGN 110.0B
- IPO Year
- BUD N/A
- REGN 1991
- Fundamental
- Price
- BUD $50.22
- REGN $701.85
- Analyst Decision
- BUD Buy
- REGN Buy
- Analyst Count
- BUD 5
- REGN 24
- Target Price
- BUD $72.33
- REGN $1,054.00
- AVG Volume (30 Days)
- BUD 2.7M
- REGN 920.8K
- Earning Date
- BUD 10-31-2024
- REGN 01-31-2025
- Dividend Yield
- BUD 1.75%
- REGN N/A
- EPS Growth
- BUD 4.16
- REGN 15.31
- EPS
- BUD 3.19
- REGN 40.43
- Revenue
- BUD $59,400,000,000.00
- REGN $13,847,100,000.00
- Revenue This Year
- BUD $3.10
- REGN $10.20
- Revenue Next Year
- BUD $3.60
- REGN $4.16
- P/E Ratio
- BUD $15.15
- REGN $17.36
- Revenue Growth
- BUD N/A
- REGN 5.72
- 52 Week Low
- BUD $49.66
- REGN $693.00
- 52 Week High
- BUD $67.49
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- BUD 22.06
- REGN 27.80
- Support Level
- BUD $52.30
- REGN $693.00
- Resistance Level
- BUD $53.99
- REGN $745.00
- Average True Range (ATR)
- BUD 0.66
- REGN 21.29
- MACD
- BUD -0.06
- REGN 0.05
- Stochastic Oscillator
- BUD 12.04
- REGN 8.20
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 it acquired SABMiller.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).